Glycolytic reprogramming through PCK2 regulates tumor initiation of prostate cancer cells.

Oncotarget 2017 Oct 28;8(48):83602-83618. Epub 2017 Jun 28.

The Basic Research Laboratory, National Cancer Institute, National Institutes of Health Frederick, Frederick, MD 21702, USA.

Tumor-initiating cells (TICs) play important roles in tumor progression and metastasis. Identifying the factors regulating TICs may open new avenues in cancer therapy. Here, we show that TIC-enriched prostate cancer cell clones use more glucose and secrete more lactate than TIC-low clones. We determined that elevated levels of phosphoenolpyruvate carboxykinase isoform 2 (PCK2) are critical for the metabolic switch and the maintenance of TICs in prostate cancer. Information from prostate cancer patient databases revealed that higher PCK2 levels correlated with more aggressive tumors and lower survival rates. PCK2 knockdown resulted in low TIC numbers, increased cytosolic acetyl-CoA and cellular protein acetylation. Our data suggest PCK2 promotes tumor initiation by lowering acetyl-CoA level through reducing the mitochondrial tricarboxylic acid (TCA) cycle. Thus, PCK2 is a potential therapeutic target for aggressive prostate tumors.

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.18787DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663539PMC
October 2017
9 Reads

Publication Analysis

Top Keywords

prostate cancer
16
tumor initiation
8
pck2
6
prostate
5
cancer
5
critical metabolic
4
lowering acetyl-coa
4
isoform pck2
4
pck2 critical
4
initiation lowering
4
cancer prostate
4
promotes tumor
4
tics prostate
4
maintenance tics
4
metabolic switch
4
switch maintenance
4
carboxykinase isoform
4
levels phosphoenolpyruvate
4
reducing mitochondrial
4
tic-low clones
4

Similar Publications